Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease ; volume:83 ; number:13 ; day:28 ; month:7 ; year:2023 ; pages:1179-1205 ; date:9.2023
Drugs ; 83, Heft 13 (28.7.2023), 1179-1205, 9.2023
- Creator
-
Gisbert, Javier P.
Chaparro, María
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-023-01916-2
- URN
-
urn:nbn:de:101:1-2023110711122598697440
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gisbert, Javier P.
- Chaparro, María
- SpringerLink (Online service)
Other Objects (12)
Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
Systematic Review and Meta-Analysis: Association between Preoperative Ustekinumab and Surgical Complications in Crohn’s Disease Patients
Elderly-onset Crohn’s disease remarkably responsive to ustekinumab: a case report
Successful Drug Desensitization to Ustekinumab in a Patient with Crohn’s Disease
Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years
Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn’s disease
Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
Systematic Review and Meta-Analysis: Association between Preoperative Ustekinumab and Surgical Complications in Crohn’s Disease Patients
Elderly-onset Crohn’s disease remarkably responsive to ustekinumab: a case report
Successful Drug Desensitization to Ustekinumab in a Patient with Crohn’s Disease
Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years
Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn’s disease
Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
Systematic Review and Meta-Analysis: Association between Preoperative Ustekinumab and Surgical Complications in Crohn’s Disease Patients
Elderly-onset Crohn’s disease remarkably responsive to ustekinumab: a case report
Successful Drug Desensitization to Ustekinumab in a Patient with Crohn’s Disease
Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years
Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn’s disease